创新药概念继续活跃，上海谊众20%涨停，南新制药涨逾16%，东诚药业涨停，辰欣药业三连板，华润 双鹤、亚太药业等大涨。 ...

Group 1 - The financing balance of the Sci-Tech Innovation Board increased by 115 million yuan compared to the previous day, marking an increase for eight consecutive trading days [1] - As of July 23, the total margin financing balance on the Sci-Tech Innovation Board reached 165.993 billion yuan, with a financing balance of 165.389 billion yuan [1] - There are 435 stocks on the Sci-Tech Innovation Board with a financing balance exceeding 100 million yuan, and 17 stocks have a financing balance over 1 billion yuan [1] Group 2 - The stock with the highest net financing purchase is Shangwei New Materials, with a latest financing balance of 26.818 million yuan, increasing by 94.9546 million yuan, and the stock rose by 19.73% on that day [2] - Other stocks with significant net purchases include Electric Wind Power and Haichuang Pharmaceutical, with net purchases of 66.8525 million yuan and 54.0988 million yuan, respectively [2] - The average increase for stocks with net purchases exceeding 10 million yuan was 0.84%, with Electric Wind Power and Shangwei New Materials leading the gains [2] Group 3 - The industry sectors favored by financing customers include pharmaceuticals, electronics, and machinery, with 13, 12, and 11 stocks respectively [2] - The average ratio of financing balance to circulating market value for stocks with significant net purchases is 4.49%, with Xinyu Ren having the highest ratio at 9.53% [2] - Other stocks with high financing balance ratios include Huahai Chengke, Yangguang Nuohuo, and Yinuosi, with ratios of 8.49%, 8.31%, and 8.00% respectively [2]

Core Viewpoint - Shanghai Kai Bao Pharmaceutical Co., Ltd. has reduced its shareholding in Shanghai Yi Zhong Pharmaceutical Co., Ltd. from 11.95% to 10.95% through a block transfer of 2,067,037 shares at a price of 53.98 yuan per share, which constitutes a 1% change in equity [1][3][5]. Shareholding Changes - After the transfer, Shanghai Kai Bao will hold 1,047,642 shares, representing 0.99% of the total share capital of Shanghai Yi Zhong [2][4]. - Prior to the transfer, Shanghai Kai Bao's shareholding was 12.01% of the total share capital [2][3]. Transfer Details - The total share capital of Shanghai Yi Zhong is 143,888,000 shares after a capital increase [2][4]. - The transfer was conducted through an inquiry process, with 11 institutional investors submitting valid bids, resulting in 8 investors being allocated shares [7][8]. Regulatory Compliance - The transfer process adhered to relevant laws and regulations, ensuring fairness and compliance with market standards [8].

证券代码：688091 证券简称：上海谊众 公告编号：2025-029 上海谊众药业股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益 变动触及 1%整数倍的提示性公告 上海凯宝药业股份有限公司（以下简称"上海凯宝"或"转让方"）保证向上 海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）提供的信息内容不 存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依 法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的价格为53.98元/股，转让的股票数量为2,067,037股。 公司控股股东、实际控制人、董事、监事及高级管理人员未参与本次询 价转让。 本次权益变动为股份减持，不触及要约收购，本次转让不会导致公司控 股股东、实际控制人发生变化。 本次权益变动后，转让方上海凯宝药业股份有限公司持有公司股份比例 由占公司总股本的11.95%减少至10.95%，持有公司权益比例变动触及 1%的整数倍。 一、 转让方情况 (一)转让方基本情况 截至 2025 年 7 月 16 日，转让方所持公司股份的数量、比例情况如下： | ...

上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"或"组织券商"）受委 托担任上海凯宝药业股份有限公司（以下简称"上海凯宝"或"转让方"）以向 特定机构投资者询价转让（以下简称"本次询价转让"）方式减持所持有的上海 谊众药业股份有限公司（以下简称"公司"或"上海谊众"）首次公开发行前已 发行股份的组织券商。 经核查，国泰海通就本次询价转让的股东、受让方是否符合《上海证券交易 所科创板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修订）》 （以下简称"《询价转让和配售指引》"）要求，本次询价转让的询价、转让过 程与结果是否公平、公正，是否符合《询价转让和配售指引》的规定作出如下报 告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 7 月 16 日，转让方所持公司股份的数量、比例情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股比例 | | --- | --- | --- | --- | | 1 | 上海凯宝 | 24,703,546 | 11.95% | 国泰海通证券股份有限公司 关于上海谊众药业股份有限公司 股东向特定机构投资者询 ...

Core Viewpoint - Shanghai Yizhong is facing significant performance pressure as its second-largest shareholder, Shanghai Kaibao, plans to reduce its stake amid high stock prices and declining earnings [2][9]. Shareholder Actions - On July 16, Shanghai Kaibao announced plans to sell up to 6.2011 million shares of Shanghai Yizhong, currently holding 24.7035 million shares, representing 11.95% of the company [2][4]. - This marks the second time Shanghai Kaibao has reduced its stake, having previously sold 1.0476 million shares in 2022 for approximately 97.2716 million yuan [2][8]. - As of July 17, Shanghai Yizhong's stock price was 67.9 yuan per share, reflecting a 70% increase year-to-date, with the current market value of Shanghai Kaibao's holdings around 1.677 billion yuan [4][9]. Company Performance - Shanghai Yizhong reported a revenue of 71.0322 million yuan in Q1 2025, a year-on-year increase of 3.39%, but net profit fell by 51.38% to 14.186 million yuan [3][10]. - The company experienced a significant decline in performance in 2024, with revenues dropping to 174 million yuan, a decrease of 51.83%, and net profit down 95.68% [10]. - The core product, paclitaxel micelles, was not included in the medical insurance directory until November 2024, impacting market access and sales performance [9][10]. Financial Metrics - In 2024, Shanghai Yizhong's sales and R&D expenses were 115 million yuan and 37.2037 million yuan, respectively, reflecting increases of 8.28% and 65.71% [10]. - For Q1 2025, sales and R&D expenses were 28.2088 million yuan and 9.2766 million yuan, accounting for 39.7% and 13.06% of total revenue [10].

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

证券代码：688091 证券简称：上海谊众 公告编号：2025-028 上海谊众药业股份有限公司 股东询价转让定价情况提示性公告 上海凯宝药业股份有限公司（以下简称"上海凯宝"或"转让方"）保证向 上海谊众药业股份有限公司（以下简称"上海谊众"或"公司"）提供的信息内容 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整 性依法承担法律责任。 （二）参与本次询价转让报价的机构投资者家数为 11 家，涵盖了基金管理 公司、合格境外投资者、证券公司及私募基金管理人等专业机构投资者，合计有 效认购股份数量为 2,975,300 股，对应的有效认购倍数约为 1.44 倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 8 家机构 投资者，拟受让股份总数为 2,067,037 股。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据2025年7月17日询价申购情况，初步确定的上海谊众股东询价转让 （以下简称"本次询价转让"）的转让价格为53.98元/股。 一、本次询价转让初步定价 （一）经向机构投资者询价后，本次询价转让初步确定的转让价格为 53. ...

Summary of Key Points Core Viewpoint - Shanghai Yizhong Pharmaceutical Co., Ltd. is planning a share transfer through a pricing inquiry, with the selling party being Shanghai Kaibao Pharmaceutical Co., Ltd. This transfer involves 2,067,037 shares, representing 1.00% of the total share capital, primarily due to the seller's funding needs [1][2][3]. Group 1: Shareholder Information - The selling party, Shanghai Kaibao, holds 2,067,037 shares, which is 8.37% of its total holdings in Shanghai Yizhong [3]. - The selling party is not a controlling shareholder, actual controller, or a member of the board or senior management of Shanghai Yizhong [1][2]. Group 2: Transfer Details - The shares being transferred have been released from restrictions and are free of any transfer limitations [2]. - The transfer will not occur through centralized bidding or block trading, and the shares acquired through this inquiry cannot be transferred within six months [3][4]. Group 3: Pricing and Transfer Conditions - The minimum transfer price will be set at no less than 70% of the average trading price over the 20 trading days prior to July 16, 2025 [4]. - The pricing will be determined based on a priority system that considers bid price, bid quantity, and the time of bid submission [4][5]. Group 4: Investor Eligibility - Eligible investors for this transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [5]. Group 5: Company Risk and Control - Shanghai Yizhong does not face any operational risks that require disclosure under the relevant stock exchange rules [6]. - The share transfer is not expected to lead to any change in control of Shanghai Yizhong [6].

国泰海通证券股份有限公司 关于上海谊众药业股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国（上海）自由贸易试验区商城路 618 号 1 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》、《科 创板上市公司持续监管办法（试行）》、《上海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售 （2025 年 3 月修订）》（以下简称"《询价转让和配售指引》"）等相关规定， 国泰海通对参与本次询价转让股东的相关资格进行核查，并出具本核查意见。 一、本次询价转让的委托 国泰海通收到出让方关于本次询价转让的委托，委托国泰海通组织实施本次 询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求，国泰海通对出让方的相关资格进行了核查。出让方已出 具《关于向特定机构投资者询价转让首次公开发行前已发行股份出让方资格相关 事宜的承诺函》。国泰海通已完成出让方资格核查工作，对出让方进行访谈和问 询，并收集相关核查文件。此外，国泰海通还通过公开信息渠道检索等手段对出 让方资格进行了核查。 （二）核查情况 | 企 ...